Journal Mobile Options
Table of Contents
Vol. 218, No. 1, 2009
Issue release date: December 2008
Dermatology 2009;218:63–66
(DOI:10.1159/000173976)

Nodular Morphea

Kauer F. · Simon J.C. · Sticherling M.
aDepartment of Dermatology and Venerology, Vivantes Klinikum Neukölln, Berlin, bDepartment of Dermatology, Venerology and Allergology, University of Leipzig, Leipzig, and cDepartment of Dermatology, Venerology and Allergology, University of Erlangen, Erlangen, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Scleroderma may present as being strictly limited to the skin, as in morphea, or within a multiorgan disease, as in systemic sclerosis. Accordingly, cutaneous manifestations vary clinically. In nodular or keloidal scleroderma, patients develop lesions that are clinically indistinguishable from a keloid; however, the histopathological findings are more variable. We describe a 16-year-old girl with morpheic lesions for 3–4 years and additional development of keloidal nodules within these lesions. The histological examination revealed a hypertrophic scar besides morphea.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Butler J, Laymon CW: Nodular diffuse scleroderma. Arch Dermatol Syphilol 1937;35:919–931.
  2. Labandeira J, Toribio J: What is nodular-keloidal scleroderma? Dermatology 2003;207:130–132.
  3. Wollina U: Extracorporeal photochemotherapy in nodular scleroderma. Br J Dermatol 1998;139:559–560.
  4. Hsu S, Kramer ME: Nodular morphea in a linear pattern. Int J Dermatol 1999;38:529–530.
  5. Barzilai A, Trau H: Keloid-like scleroderma. Am J Dermatopathol 2003;25:327–330.
  6. Kubo M, Tamaki K: Keloid-like morphea. Acta Derm Venereol 1997;77:90–91.
  7. Melani L, Fabbri P: A case of nodular scleroderma. J Dermatol 2005;32:1028–1031.
  8. Weedon D: Skin Pathology, ed 2. New York, Churchill Livingstone, 2002, pp 357–358.
  9. Yamamoto T, Nishioka K: Nodular scleroderma: increased expression of connective tissue growth factor. Dermatology 2005;211:218–223.
  10. Wollina U: Nodular scleroderma – successful treatment with extracorporeal photo chemotherapy. Indian J Dermatol 2000;45:157–160.
  11. Soria A, Cario-André M, Lepreux S, Rezvani HR, Pasquet JM, Pain C, Schaeverbeke T, Mahon FX, Taïeb A: The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study. Dermatology 2008;216:109–117.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00